Object-To ascertain the management of inflammatory smear results by general practitioners. Design-Postal questionnaire survey.
Introduction
Inflammatory changes on cervical cytology are not infrequently associated with sexually transmitted infection' and it is well recognised that more than one sexually transmitted disease may coexist making screening for other infections advisable. 2 Cytopathological appearances on the Papanicolau smear may suggest specific pathogens: Trichomonas vaginalis, candida species, Gardnerella vaginalis, human papilloma virus, Chlamydia trachomatis and herpes simplex virus, but the sensitivity and specificity in respect of Chlamydia trachomatis is disputed. '3 As a result of the British Society for Clinical Cytology working party recommendation7 abnormal smear results are accompanied by advice on management; for example, "investigate, treat and repeat" is now added to a report where inflammatory changes are seen on cervical cytology.
A recent study in the community8 found 5% of smears taken in one year in one general practice were reported as inflammatory, almost half of which had microbiologically proven infection when subsequently investigated, the commonest infecting organisms being gardnerella and candida, which agrees with the findings of an earlier study in general practice .9 In another community based study where patients with inflammatory smears were referred to a department of genitourinary medicine for investigation, genital infection was found in three quarters, a fifth of whom had coexistent infection.' The prevalence of Chlamydia trachomatis in this study was 18% (previous studies have shown prevalences of 5.7%-7.3%). [9] [10] [11] [12] In view of this the authors suggested that, notwithstanding the constraints of the service, certain categories of patients should be referred to departments of genitourinary medicine for further investigation whilst the remaining patients ( Follow-up was ensured by 33 (30%) doctors using their own computer recall system, 44 (40%) using a manual recall system of either a diary, tagging notes or keeping a separate list of abnormal results; five (5%) relied on the FHSA computer recall; 16 (15%) relied on the patient to ensure their own follow up having explained the need for this. Eleven (10%) of doctors did not specify how they followed patients up.
Attitudes to the importance of screening for sexually transmitted diseases (STDs) in patients with inflammatory smears covered a range of views: 16 (14%) doctors thought it obligatory, 54% desirable but not essential; 30% unlikely to be cost effective; 9 did not express a view. Table 2 shows what investigations are undertaken if a report of "inflammatory cells, investigate, treat and repeat" is received.
The swab most commonly taken is that of high vaginal swab (HVS): 99 (88%) of respondents cite this as one they would take. Forty eight of the 112 said an HVS would be Thirty seven (64%) replied that they gave either tetracycline or erythromycin (both effective against chlamydial infection) again usually in combination with either metronidazole and/or an antifungal agent.
Six gave antifungal agents alone, four gave metronidazole alone and one doctor used sultrin only. Three used cephalosporins in combination with metronidazole and one gave betadine pessaries with metronidazole. Table  3 lists the medication used to treat patients with inflammatory smear results without microbiological evidence of infection. Table 4 shows the time allowed to elapse before repeat smears are performed. This ranges from three weeks to one year, the majority being performed within three months. Twenty four doctors said that they followed the laboratory recommendation (normally repeating the smear 2-6 weeks after treatment) and two of these relied on computer recall by the FHSA. Of 109 doctors who replied, 79 (72%) felt that the advice on further management given on the smear report was clinically relevant and helpful; 29 (27%) were not satisfied. One hundred and six (97%) answered that more detailed advice, for example, a suggestion of the likely pathogen, would be desirable.
Doctors were asked where they referred patients when colposcopy was advised on the smear report; three general practitioners failed to answer this part of the questionnaire. Of the remaining 109 doctors 109 (100%) referred the patient to a gynaecologist. Additionally, three occasionally referred the patient to a GUM department and one specified colposcopy clinic.
Concerning male sexual partners of patients with inflammatory smears, 76 (70%) doctors said they would not ask them to visit either their family doctor or the GUM department. Thirty one (28%) doctors would ask them to attend their own family doctor (of these 13 would alternatively ask them to attend the GUM department). In total 94 (86%) would not ask them to attend the GUM department. Again, three doctors failed to answer this question.
Finally, general comments on the subject of inflammatory smear results were invited and these are considered in the discussion. Many doctors used the questionnaire as an opportunity to air their concern regarding the management of inflammatory smears. The apparent commonality of the inflammatory smear report and the impression that it often may return to normal on repeat testing was mentioned by several doctors. Ten doctors asked if a protocol for management could be drawn up or if more specific help in the likely cause of infection could be given. It is apparent that few patients, or their partners, are referred to GUM departments following an inflammatory smear report for investigation. It would, therefore, seem prudent that, if patients are to be managed by their general practitioner that guidelines be issued, either as a local protocol or possibly in the form of a notice attached to the smear report, with regard to further investigation and treatment with and indication as to when referral to a GUM Department might be appropriate.
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